RS54770B1 - Određivanje efikasnosti žive rekombinantne anti-mikobakterijske vakcinacije - Google Patents

Određivanje efikasnosti žive rekombinantne anti-mikobakterijske vakcinacije

Info

Publication number
RS54770B1
RS54770B1 RS20160350A RSP20160350A RS54770B1 RS 54770 B1 RS54770 B1 RS 54770B1 RS 20160350 A RS20160350 A RS 20160350A RS P20160350 A RSP20160350 A RS P20160350A RS 54770 B1 RS54770 B1 RS 54770B1
Authority
RS
Serbia
Prior art keywords
efficacy
determination
recombinant anti
live recombinant
mycobacterial
Prior art date
Application number
RS20160350A
Other languages
English (en)
Inventor
Christiane Desel
Stefan H E Kaufmann
Silke Bandermann
Leander Grode
Original Assignee
Max-Planck-Gesellschaft Zur Förderung Der Wss E V
Vakzine Projekt Man Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Planck-Gesellschaft Zur Förderung Der Wss E V, Vakzine Projekt Man Gmbh filed Critical Max-Planck-Gesellschaft Zur Förderung Der Wss E V
Publication of RS54770B1 publication Critical patent/RS54770B1/sr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Postupak za određivanje efikasnosti rekombinantne mikobakterijske žive vakcine, koji sadrži određivanje T pomoćnog tipa 17 (Th17) imunog odgovora u vakcinisanom subjektu, pri čemu je detektabilni Th17 imuni odgovor indikativan za zaštitni imunitet kod navedenog subjekta.Prijava sadrži još 10 patentnih zahteva.
RS20160350A 2010-12-21 2011-12-21 Određivanje efikasnosti žive rekombinantne anti-mikobakterijske vakcinacije RS54770B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061425442P 2010-12-21 2010-12-21
EP11805020.2A EP2656070B9 (en) 2010-12-21 2011-12-21 Determination of the efficacy of a live recombinant anti-mycobacterial vaccination
PCT/EP2011/073609 WO2012085099A1 (en) 2010-12-21 2011-12-21 Determination of the efficacy of an anti-mycobacterial vaccination

Publications (1)

Publication Number Publication Date
RS54770B1 true RS54770B1 (sr) 2016-10-31

Family

ID=45446021

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160350A RS54770B1 (sr) 2010-12-21 2011-12-21 Određivanje efikasnosti žive rekombinantne anti-mikobakterijske vakcinacije

Country Status (25)

Country Link
US (1) US8906389B2 (sr)
EP (1) EP2656070B9 (sr)
JP (1) JP6055780B2 (sr)
KR (1) KR101882040B1 (sr)
CN (1) CN103492877B (sr)
AU (1) AU2011347266B2 (sr)
BR (1) BR112013015878B1 (sr)
CA (1) CA2822715C (sr)
CU (1) CU20130084A7 (sr)
CY (1) CY1117412T1 (sr)
DK (1) DK2656070T3 (sr)
EA (1) EA029833B9 (sr)
ES (1) ES2569035T3 (sr)
HK (1) HK1192322A1 (sr)
HR (1) HRP20160558T1 (sr)
HU (1) HUE027781T2 (sr)
MX (1) MX345961B (sr)
PL (1) PL2656070T3 (sr)
PT (1) PT2656070E (sr)
RS (1) RS54770B1 (sr)
SG (1) SG191331A1 (sr)
SI (1) SI2656070T1 (sr)
SM (1) SMT201600149B (sr)
UA (2) UA112067C2 (sr)
WO (1) WO2012085099A1 (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543698A1 (en) * 2018-03-20 2019-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH Method for determining vaccine efficacy in an individual and means therefore

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
EP1137769B1 (en) * 1998-11-10 2008-09-03 University Of Rochester Methods for the generation of dna libraries
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
JP2001215224A (ja) * 1999-11-25 2001-08-10 Hitachi Chem Co Ltd 免疫反応のアッセイ法、免疫学的判定法及びアッセイキット
JP4662925B2 (ja) 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン
BRPI0606991A2 (pt) * 2005-02-14 2009-08-18 Wyeth Corp métodos para triar compostos de teste capazes de antagonizar a sinalização de il-17f, para diagnosticar um distúrbio relacionado com a sinalização aumentada de il-17f em um indivìduo, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-21, in vitro para inibir pelo menos uma atividade associada com a sinalização de il-23, para purificar a proteìna il-17a natural, e para isolar heterodìmeros de il-17 a/il-17f substancialmente isentos de homodìmeros de il-17a e homodìmeros de il-17f, uso de uma quantidade terapeuticamente eficaz de um antagonista da sinalização de il-17f, composição farmacêutica, adjuvante de vacina, anticorpo isolado, proteìnas il-17f e il-17a isoladas, e, heterodìmero de il-17a/il-17f
BRPI0713133A2 (pt) * 2006-06-19 2012-03-27 Wyeth Corp métodos de modular il-22 e il-17
CN101329230B (zh) * 2008-07-14 2010-10-20 中国人民解放军第三军医大学 改进的免疫荧光细胞染色方法
JP2010051307A (ja) * 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
RU2473365C1 (ru) 2008-10-20 2013-01-27 Юниверсити Оф Цюрих Вакцина mycobacterium tuberculosis
AU2010273708B2 (en) * 2009-06-29 2015-10-01 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae

Also Published As

Publication number Publication date
HRP20160558T1 (hr) 2016-06-17
CN103492877B (zh) 2015-04-01
DK2656070T3 (en) 2016-06-13
EP2656070B1 (en) 2016-03-09
CU20130084A7 (es) 2013-12-27
SI2656070T1 (sl) 2016-05-31
EP2656070B9 (en) 2017-01-04
KR20140020243A (ko) 2014-02-18
BR112013015878B1 (pt) 2020-10-27
US20130280739A1 (en) 2013-10-24
HK1192322A1 (en) 2014-08-15
KR101882040B1 (ko) 2018-07-25
BR112013015878A2 (pt) 2016-10-04
UA113282C2 (xx) 2017-01-10
AU2011347266A1 (en) 2013-07-25
SMT201600149B (it) 2016-07-01
ES2569035T3 (es) 2016-05-06
UA112067C2 (uk) 2016-07-25
JP6055780B2 (ja) 2016-12-27
EP2656070A1 (en) 2013-10-30
US8906389B2 (en) 2014-12-09
EA029833B1 (ru) 2018-05-31
CA2822715C (en) 2019-04-30
SG191331A1 (en) 2013-07-31
JP2014502841A (ja) 2014-02-06
PT2656070E (pt) 2016-06-17
PL2656070T3 (pl) 2017-01-31
EA201300738A1 (ru) 2013-12-30
EA029833B9 (ru) 2018-06-29
CN103492877A (zh) 2014-01-01
CA2822715A1 (en) 2012-06-28
MX345961B (es) 2017-02-28
HUE027781T2 (en) 2016-11-28
AU2011347266B2 (en) 2016-07-21
WO2012085099A1 (en) 2012-06-28
MX2013007244A (es) 2014-01-17
CY1117412T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
AR118199A2 (es) Composiciones inmunogénicas de variantes no lipidadas no piruviladas de antígenos orf2086 de neisseria meningitidis, polipéptidos, secuencias de nucleótidos y plásmidos
EA201691348A1 (ru) Однофлаконные вакцинные составы
BR112013010288A2 (pt) método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
CO6781540A2 (es) Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
EA201070219A1 (ru) Полимерные мультиэпитопные вакцины против гриппа
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
NZ729519A (en) Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
UY36395A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
BR112015009541A2 (pt) novos adjuvantes de mucosa e sistemas de aplicação
BR112013004236A2 (pt) formulações estáveis de antígenos de neisseria meningitidis rlp2086
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
MX2013015198A (es) Vacuna del corona virus canino.
BR112014014319A2 (pt) composições de cuidado oral
IN2014CN03454A (sr)
EA201791957A1 (ru) Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
FI20115374A0 (fi) Uudet hypoallergeenit
PH12014502015B1 (en) Novel veterinary vaccine
RS54770B1 (sr) Određivanje efikasnosti žive rekombinantne anti-mikobakterijske vakcinacije
GB2515222A (en) Use of flagellin as a vaccine
MX2014009022A (es) Virus de influenza c y vacuna.
EA201300380A1 (ru) Рекомбинантная mycobacterium в качестве вакцины для применения у людей